Market Overview

UPDATE: Bank Of America Reiterates On Pacira Pharmaceuticals On Positive Survey Results

Related PCRX
5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm
Wedbush Thinks Pacira Pharma Is Worth $106 On Exparel Sales
Premarket Biotech Digest: Anavex Uplisting, Discount On PCSK9 Inhibitors, Exact Sciences Plunges (Seeking Alpha)

In a report published Thursday, Bank of America analyst Steve Byrne reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised the price target from $86.00 to $104.00.

In the report, Bank of America noted, “We are raising our PO to $104 (from $86) based on positive results from our Exparel survey, including a meaningful change in the outlook from anesthesiologists and expectations for significant revenue growth. We see upside from use in the nerve block indication (March 5, 2015 PDUFA date) as anesthesiologists in our survey stated they would use Exparel in roughly half of their nerve block procedures if approved.

"We modestly adjusted our peak market share in nerve block to 25% (from 20%) and increased our 2021 peak sales to $2.3bn (from $2.1bn), which assumes some IP extension potential (spray based technology would extend IP to 2031) and expansion of PCRX' manufacturing capacity (readily replicable in our view). We see upside from other DepoFoam–derived products such as NSAIDs.”

Pacira Pharmaceuticals closed on Wednesday at $85.14.

Latest Ratings for PCRX

Oct 2015Leerink SwannMaintainsMarket Perform
Sep 2015NomuraInitiates Coverage onBuy
Jul 2015Bank of AmericaUpgradesUnderperformNeutral

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: Bank of America Steve ByrneAnalyst Color Price Target Analyst Ratings


Related Articles (PCRX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters